

Mode of action of enoxaparin in plasma

Citation for published version (APA):

Beguin, S., & Hemker, H. C. (1990). Mode of action of enoxaparin in plasma. *Acta chirurgica Scandinavica. Supplementum*, 556, 51-56.

Document status and date:

Published: 01/01/1990

Document Version:

Publisher's PDF, also known as Version of record

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

MODE OF ACTION OF ENOXAPARIN IN PLASMA

Suzette Béguin and H. Coenraad Hemker

Department of Biochemistry, University of Limburg, Maastricht, The Netherlands

Abstract. Unfractionated heparin in the extrinsic system has an action on prothrombinase that is insignificant compared to its antithrombin action. In the intrinsic system, unfractionated heparin does have an indirect antiprothrombinase action because its antithrombin activity inhibits the feedback activation of Factor VIII. Most low molecular weight heparins are not different from unfractionated heparin, although their antiprothrombinase action may be slightly higher. Among these, enoxaparin has the highest antiprothrombinase action, due to a relatively high content of very low molecular weight material. In platelet rich plasma, there is an important difference between unfractionated and low molecular weight heparin in that, up to 0.3 U/ml, unfractionated heparin is completely neutralized by activated platelets (300 000 μ l/l) whereas low molecular weight heparins are not. Therefore, unfractionated heparin in platelet rich plasma acts only on the lag phase of thrombin production and not on the amount of thrombin produced. Low molecular weight heparins significantly prolong the lag time and inhibit the thrombin peak in platelet rich plasma.

Key words: enoxaparin, low molecular weight heparin, thrombin, prothrombinase, platelet Factor 4, feedback regulation, platelet rich plasma.

Considering the mode of formation of thrombin in plasma, as it is schematically represented in Fig. 1, it can be seen that an anticoagulant product can act according to at least two essentially different pathways. It can act (Fig. 2) directly on thrombin via the catalysis of physiological antiproteases such as antithrombin III (AT III) or heparin cofactor II (HC II) or indirectly by reducing the amount of thrombin generated from prothrombin either by decreasing the prothrombin level, or by acting on the components of the prothrombinase complex, i.e. the activated Factors X and V on a phospholipid surface.

The antagonists of the vitamin K-dependent factors represent a typical example of inhibition of thrombin formation, acting on the Factors II, VII, IX and X. Vitamin K antagonists thus have a typical antiprothrombinase action. Now the question arises: is it necessary to inhibit all of these factors to obtain this

inhibition of prothrombinase or only one and, in the latter case, which one? According to a method that has been extensively described elsewhere by these authors (4) the course of prothrombinase activity of the clotting plasmas of patients with anti-vitamin K therapy has been estimated (5). For each vitamin K-dependent factor separately (Factors II, VII, IX and X), the prothrombinase was measured after having supplemented the plasma with the three other purified clotting factors. Figure 3 shows no significant decrease of the prothrombinase activity for the factors VII, IX and X until about 5% of the activity of their normal values. However, in the same figure it can be observed that the prothrombinase activity is directly related to the prothrombin concentration of the plasma. Thus, it appears that prothrombin and consequently thrombin must be the main target for an anticoagulant treatment.

It is known that unfractionated heparin (UFH) inhibits the activated Factors X, IX, XI and thrombin via its AT III cofactor activity. It has been previously demonstrated by the authors (1) that unfractionated heparin (UFH), contrary to the generally accepted view, has hardly any influence on prothrombinase formation triggered via the extrinsic pathway, i.e. by recalcification of plasma in the presence of thromboplastin, as shown in Fig. 4. Its role is essentially that of a catalyst of AT III dependent thrombin inactivation only. Why does the anti-Xa property of unfractionated heparin not play a role in the prothrombinase complex inhibition? As shown in Fig. 3 and as can be seen in Fig. 5, it is necessary to inhibit Factor Xa almost completely, in order to influence thrombin formation via the inhibition of prothrombinase. [This experiment (Fig. 5) was carried out by Lindhout and Pieters (3)]. It demonstrates that when the courses of thrombin and Xa concentration are followed simultaneously in the same thromboplastin-activated plasma, the thrombin peak appears earlier than the Xa peak. During the




Fig. 1. A scheme of thrombin formation including the feedback mechanisms.

maximum of prothrombin conversion, there is hardly any Factor Xa present. Therefore, it can be concluded that only traces of Xa are necessary to produce a thrombin explosion. Inhibition of Factor Xa therefore has to be important before it starts influencing prothrombin conversion. When in the presence of heparin, coagulation is triggered via the intrinsic pathway (kaolin and phospholipid). An




Fig. 2. Possible modes of inhibition of coagulation by an antithrombotic product.




Fig. 3. Relationship between prothrombinase activity and the concentration of vitamin K-dependent factors.




Fig. 4. Influence of unfractionated heparin on the thrombin and prothrombinase generation in thromboplastin activated plasma. Control ●-●; heparin (U/ml): ○-○ 0.03; ▲-▲ 0.04; ●-● 0.05; ○-○ 0.1.




Fig. 5. Kinetics of thrombin and Factor Xa generation simultaneously measured in thromboplastin activated plasma in the presence of unfractionated heparin and pentasaccharide. Control: ○-○ thrombin; ▲-▲ Xa; ●-● prothrombinase. Factor Xa generation: heparin (U/ml): △-△ 0.05; ▲-▲ 0.01; pentasaccharide: *25 μg/ml.

inhibition of the prothrombinase activity and also a prolongation of the lag phase before the apparition of thrombin was observed (1). It can be assumed that this is because the AT III-heparin complex inhibits the earliest traces of thrombin (prolongation of the lag phase) required to convert Factor VIII into Factor VIIIa. Factor VIIIa is required to protect Factor IXa from the AT III-heparin inactivation (Fig. 6). In the absence of Factor VIIIa, Factor IXa (a) can hardly activate Factor X and (b) is readily inhibited by AT III-heparin. Thus, again, it appears that thrombin must be the primary target of an anticoagulant product. Because thrombin enhances its own formation via the mechanism of feedback reactions (Fig. 1), thrombin inhibition causes, secondarily, inhibition of prothrombinase.

Most low molecular weight heparins (LMWHs) tested are not different from UFH, although their antiprothrombinase action may be slightly higher. As shown in Fig. 7, enoxaparin inhibits thrombin in a dose-dependent way. Contrary to most other heparins, it also inhibits the prothrombinase activity in




Fig. 7. Influence of enoxaparin on the generation of thrombin in plasma via the extrinsic (curves A, B, C) and intrinsic (curves D, E, F) pathways. A and D: no heparin; B and E: 0.6 $\mu\text{g/ml}$; C and F: 1.2 $\mu\text{g/ml}$.




Fig. 6. A scheme of the action of AT III-heparin complex in plasma.

the extrinsic pathway (Fig. 8) Why this difference? enoxaparin is a mixture; and when properly fractionated, two of its major components, fraction A (EMT 966 of relatively high molecular weight) and fraction B (EMT 967 of relatively low molecular weight), have been found to possess different properties (2). As summarized in Table I, fraction A, like UFH (S type heparin), acts primarily on thrombin formed and not on prothrombinase. In contrast, fraction B has no direct effect on thrombin. At high concentration, it inhibits the prothrombinase complex [P type heparin (3)].

In an attempt to investigate the action in a situation nearer to in-vivo circumstances the effect of enoxaparin and its fractions on thrombin generation in platelet rich plasma was studied (Fig. 9). As previously found for UFH (1) enoxaparin was observed to induce a prolongation of the lag phase before the appearance of the thrombin burst. Contrary to UFH, enoxaparin also inhibits the peak of thrombin. It has been shown by the authors (1) that up to 0.05 U/ml of UFH is practically completely inactivated by activated platelets. This means that UFH in platelet rich plasma (PRP) postpones the thrombin burst but




Fig. 8. Thrombin and prothrombinase inhibitions by two batches (white and black symbols) of enoxaparin in thromboplastin activated plasma. The inhibitions are expressed in per cent of the top of the peak of the uninhibited control run in parallel.




Fig. 9. Influence of enoxaparin and two of its major components on thrombin generation in platelet rich plasma. ● Control; EMT 966 µg/ml: △ 1.3; EMT 967 µg/ml: ○ 0.7; enoxaparin µg/ml: ■ 4; ▲: EMT 966 1.3 µg/ml + 0.7 µg/ml EMT 967 (recombined enoxaparin).

Table I. Inhibition of extrinsic coagulation by the two major components of enoxaparin. The inhibitions are expressed in per cent of an uninhibited control run in parallel

	Concentration ($\mu\text{g/ml}$)	Inhibition (%)	
		Thrombin	Prothrombinase
EMT 966	0.35	60	8
(Fraction A)	0.5	72	30
EMT 967	5	47	42
(Fraction B)	10	79	64

hardly inhibits it, while enoxaparin does inhibit the generation of thrombin, most probably because enoxaparin presents a lower susceptibility to platelet Factor 4 (4) released by activated platelets. This may be an example of a general mechanism by which LMWHs that by themselves are inactive but may, in platelet rich plasma, potentiate the action of active heparin components.

In conclusion, enoxaparin is a mixed type heparin which inhibits both thrombin and prothrombinase generation. It is likely that enoxaparin influences the generation of thrombin primarily, by its relatively high molecular weight fraction (S type component) and secondarily by its P type component, i.e. the relatively low molecular weight fraction. Inhibiting thrombin, enoxaparin can also inhibit the feedback mechanism, inducing an inhibition of prothrombinase, possibly reinforced by anti-Factor Xa property of its P type fraction.

Probably, the weak susceptibility to platelet Factor 4 is more relevant for the efficacy of enoxaparin in the in vivo situation than its slightly different mechanism of anticoagulation per se.

These results impact on the problem of standardization of heparins. At least three different properties of heparin will determine its effect in vivo: (a) antithrombin activity, (b) antiprothrombinase activity and (c) platelet Factor 4 sensitivity. The optimal combination of properties of heparin is not known, but careful characterization and correlation of these properties with clinical observations may eventually give the answer.

REFERENCES

1. Béguin S, Lindhout T, Hemker HC. The mode of action of heparin in plasma. *Thromb Haemostas* 1989; 60: 457-462.
2. Béguin S, Mardiguian J, Lindhout T, Hemker HC. The mode of action of low molecular weight heparin preparation (PK 10169) and two of its major components on thrombin generation in plasma. *Thromb Haemostas* 1989; 61: 30-34.
3. Hemker HC. The mode of action of heparin in plasma. In: Verstraete M, Vermeylen J, Lijnen HR, Arnout J, eds. XIth Congress on Thrombosis and Haemostasis. Brussels. Leuven: Leuven University Press 1987: 17-36.
4. Hemker HC, Williams GM, Béguin S. A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. *Thromb Haemostas* 1986; 116: 492-499.
5. Xi M, Béguin S, Hemker HC. The relative importance of the factors II, VII, IX and X for the prothrombinase activity in plasma of orally anticoagulated patients. *Thromb Haemostas* 1989; 62: 788-791.